<DOC>
	<DOCNO>NCT02750891</DOCNO>
	<brief_summary>This phase 1/2 , uncontrolled , open-label , multicenter study patient recurrent relapse diffuse intrinsic pontine glioma , glioblastoma , grade III IV glioma .</brief_summary>
	<brief_title>A Study DSP-7888 Pediatric Patients With Relapsed Refractory High Grade Gliomas</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<criteria>1 . Patients meet condition ) c ) : 1 . Have diagnosis diffuse intrinsic pontine glioma basis image finding magnetic resonance imaging ( MRI ) clinical course 2 . Have histologically cytologically confirm glioblastoma 3 . Not meet ) b ) , histologically cytologically confirm grade III IV glioma 2 . Patients able hospitalized initial dose DSP7888 end postinitial dose observation ( In Phase 1 part , patient may permit temporary overnight leave hospitalization . ) 3 . Patients age &lt; 20 year time inform consent 4 . Patients either legally acceptable representative patient ( age ≥ 16 year ) provide write voluntary consent participation study fully receive understand information study , include study objective , content , expect pharmacological action effect , foreseeable risk 5 . Patients standard therapy fail standard therapy establish 6 . Diffuse intrinsic pontine glioma patient must receive radiotherapybased treatment chemotherapy ( radiotherapy indicate ) least one cycle subsequently tumor enlargement accompany tumorrelated symptomatic worsening ( except worsen due dose reduction steroid therapy brain edema ) 7 . Glioblastoma patient grade III IV glioma patient must radiologically evident tumor reenlargement recurrence 8 . Patients ECOG PS score 0 2 enrollment . Patients PS score 3 4 due neurological symptom associate primary disease may eligible appropriate opinion investigator subinvestigator . 9 . Patients life expectancy 2 month ( 60 day ) 10 . Patients HLA type HLAA*24:02 A*02:01/06 11 . Patients adequate major organ function meet follow criterion basis laboratory data within 28 day enrollment : Neutrophil count : 1000/μL Platelet count : 5.0 ×104/μL Hemoglobin : 9.0 g/dL Serum creatinine : 2fold upper limit normal range study site ( ULN ) Total bilirubin : 2fold ULN AST , ALT : 3fold ULN 12 . Female patient childbearing potential must negative pregnancy test within 4 week ( 28 day ) enrollment 13 . Female patient childbearing potential male patient female partner childbearing potential must agree use appropriate contraception time consent 180 day last dose study drug avoid pregnancy 1 . Patients grade 3 infection accord CTCAE v4.0 2 . Patients positive test result HIV antibody , HBs antigen , HCV antibody 3 . Patients multiple disseminated primary lesion ( Multiple nodule tumor cavity acceptable . ) 4 . Patients malignancies 5 . Patients significant disease enrollment may affect study treatment , New York Heart Association ( NYHA ) Functional Class III IV heart disease , CTCAE v4.0 grade 3 arrhythmia , angina pectoris , abnormal electrocardiogram finding , interstitial pneumonia pulmonary fibrosis 6 . Patients uncontrollable complication 7 . Patients underwent allogeneic hematopoietic stem cell transplant 8 . Patients receive follow treatment within specified period enrollment Nitrosoureas , mitomycin C : &lt; 42 day Chemotherapy ( include moleculartargeted drug ) , radiotherapy : &lt; 21 day Surgery , blood transfusion , erythropoiesisstimulating drug , endocrine therapy , immunotherapy ( include biological response modifier [ BRM ] therapy ) : &lt; 14 day 9 . Pregnant breastfeed woman 10 . Patients concurrent autoimmune disease history chronic recurrent autoimmune disease , patient require longterm systemic steroid therapy ( exclude therapy give PRN basis ) . However , steroid therapy brain edema ( prednisoloneequivalent dose 30 mg/m2 ) steroid replacement therapy physiologic dose acceptable . 11 . Patients ongoing CTCAE v4.0 grade 2 adverse effect prior treatment ( exclude alopecia phlebitis ) 12 . Patients receive investigational product postmarketing study drug within 4 week ( 28 day ) enrollment 13 . Patients history allergy oilbased agent 14 . Patients previously receive DSP7888containing WT1 peptide , WT1 immunotherapy 15 . Patients inappropriate participation study reason opinion investigator subinvestigator</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>high grade glioma</keyword>
	<keyword>HGG</keyword>
	<keyword>DIPG</keyword>
</DOC>